Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Santhera Pharmaceuticals has entered into an exclusive license agreement with BioLineRx, covering Santhera's pre-clinical melanocortin-4 receptor (MC-4R) antagonist program currently in development for the treatment of cancer cachexia.
Subscribe to our email newsletter
Under the agreement, BioLineRx acquires all rights to develop, sub-license and commercialise the compound.
BioLineRx will cover all future costs of the program. Santhera will receive 22% to 25% of all BioLineRx’s sub-licensing income or royalties on future sales by BioLineRx.
Santhera CEO Klaus Schollmeier said that BioLineRx is the best partner for development of their selective, first-in-class MC-4R antagonists based on their excellent track record in developing similar stage assets to proof-of-concept in man.
The agreement with BioLineRx fits well with Santhera’s strategy to focus on its core late stage or marketed assets Catena, fipamezole and omigapil," Schollmeier said.